MX2010007500A - Anticuerpo anti-cldn6. - Google Patents

Anticuerpo anti-cldn6.

Info

Publication number
MX2010007500A
MX2010007500A MX2010007500A MX2010007500A MX2010007500A MX 2010007500 A MX2010007500 A MX 2010007500A MX 2010007500 A MX2010007500 A MX 2010007500A MX 2010007500 A MX2010007500 A MX 2010007500A MX 2010007500 A MX2010007500 A MX 2010007500A
Authority
MX
Mexico
Prior art keywords
cldn6
antibody
high level
human cldn6
activity
Prior art date
Application number
MX2010007500A
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Shuichi Tsutsumi
Kunihiro Nishimura
Hirofumi Sakumoto
Shigeto Kawai
Original Assignee
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40853092&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010007500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tokyo filed Critical Univ Tokyo
Publication of MX2010007500A publication Critical patent/MX2010007500A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describe un anticuerpo capaz de enlazarse a la Claudina-6 (CLDN6) el cual se expresa sobre la superficie de una membrana celular. El anticuerpo puede reconocer la CLDN6 humana que ocurre sobre la superficie de una membrana celular en su forma nativa, y tiene una actividad citotóxica (por ejemplo, una actividad de ADCC y una actividad de CDC) contra una línea de células cancerosas la cual expresa la CLDN6 humana a alto nivel. Un conjugado del anticuerpo y una toxina tiene una actividad inhibitoria sobre la proliferación celular de una línea de células cancerosas la cual expresa la CLDN6 humana a alto nivel. La expresión de la CLDN6 humana no se observa en un tejido normal, pero se incrementa en un tejido tumoral (por ejemplo, adenocarcinoma pulmonar, cáncer gástrico, cáncer ovárico). Se espera que el anticuerpo antiCLDN6 se acumule elevadamente en un tumor en el cual la CLDN6 humana ha sido expresada a alto nivel, y por lo tanto se puede utilizar como un agente anti-tumoral extremadamente efectivo.
MX2010007500A 2008-01-11 2009-01-09 Anticuerpo anti-cldn6. MX2010007500A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008004423 2008-01-11
PCT/JP2009/000082 WO2009087978A1 (ja) 2008-01-11 2009-01-09 抗cldn6抗体

Publications (1)

Publication Number Publication Date
MX2010007500A true MX2010007500A (es) 2010-10-20

Family

ID=40853092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007500A MX2010007500A (es) 2008-01-11 2009-01-09 Anticuerpo anti-cldn6.

Country Status (12)

Country Link
US (1) US9274119B2 (es)
EP (3) EP2241578B1 (es)
JP (1) JP5848863B2 (es)
KR (1) KR20100116179A (es)
CN (1) CN101918450A (es)
AU (1) AU2009203464A1 (es)
BR (1) BRPI0907237A2 (es)
CA (1) CA2711557A1 (es)
MX (1) MX2010007500A (es)
RU (1) RU2010133547A (es)
SG (1) SG187457A1 (es)
WO (1) WO2009087978A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2398902T3 (pl) 2009-02-20 2024-02-26 Astellas Pharma Inc. Sposoby i kompozycje do diagnozowania i leczenia nowotworu złośliwego
US8921058B2 (en) 2009-10-26 2014-12-30 Externautics Spa Prostate tumor markers and methods of use thereof
US10288617B2 (en) 2009-10-26 2019-05-14 Externautics Spa Ovary tumor markers and methods of use thereof
NO2499161T3 (es) * 2009-11-11 2018-02-03
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
ES2617283T3 (es) 2010-02-24 2017-06-16 Immunogen, Inc. Inmunoconjugados contra el receptor 1 de folato y usos de los mismos
PL2581113T3 (pl) * 2010-06-11 2018-11-30 Kyowa Hakko Kirin Co., Ltd. Przeciwciało anty-tim-3
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CN108743965A (zh) 2011-04-01 2018-11-06 伊缪诺金公司 用于增加folr1癌症治疗的功效的方法
ES2703936T3 (es) * 2011-05-13 2019-03-13 Ganymed Pharmaceuticals Gmbh Anticuerpos para el tratamiento de un cáncer que expresa la claudina 6
AU2012258087B2 (en) * 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
EA031069B1 (ru) * 2012-02-17 2018-11-30 Сиэтл Дженетикс, Инк. АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
US9200073B2 (en) 2012-08-31 2015-12-01 Immunogen, Inc. Diagnostic assays and kits for detection of folate receptor 1
JP2014193853A (ja) * 2013-03-01 2014-10-09 Japan Health Sciences Foundation 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
UA120166C2 (uk) 2013-08-30 2019-10-25 Іммуноджен, Інк. Антитіло, що специфічно зв'язується з folr1, та спосіб виявлення рецептора фолієвої кислоти 1
SG11201603397QA (en) * 2013-11-06 2016-05-30 Stemcentrx Inc Novel anti-claudin antibodies and methods of use
JPWO2015068847A1 (ja) 2013-11-11 2017-03-09 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
US10370423B2 (en) * 2014-04-01 2019-08-06 Biotech Cell & Gene thrapies GMBH Claudin-6-specific immunoreceptors and T cell epitopes
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
CN106146666B (zh) * 2015-03-26 2019-09-06 科济生物医药（上海）有限公司 靶向cldn6的免疫效应细胞及其制备方法和应用
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US11479601B2 (en) 2016-06-29 2022-10-25 The Regents Of The University Of California Antibodies specific to Sonic Hedgehog and method of use thereof
US11078271B2 (en) 2016-12-28 2021-08-03 Osaka University Anti-claudin-2 monoclonal antibody
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
AU2018334434A1 (en) * 2017-09-18 2020-04-02 The Regents Of The University Of California Claudin6 antibodies and methods of treating cancer
EP3690038A4 (en) 2017-09-29 2021-05-19 Daiichi Sankyo Company, Limited ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
WO2019111871A1 (en) 2017-12-05 2019-06-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
JP2021510064A (ja) * 2018-01-05 2021-04-15 中外製薬株式会社 細胞傷害誘導治療剤
JP2022521723A (ja) 2019-02-15 2022-04-12 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
CN113631229A (zh) 2019-03-25 2021-11-09 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
CA3139250A1 (en) * 2019-07-10 2021-01-14 Naoki Kimura Claudin-6 binding molecules and uses thereof
US11827709B2 (en) 2019-12-05 2023-11-28 Seagen Inc. Anti-AVB6 antibodies and antibody-drug conjugates
MX2022012092A (es) 2020-03-31 2022-10-13 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.
UY39507A (es) 2020-11-06 2022-03-31 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
WO2022183502A1 (zh) * 2021-03-05 2022-09-09 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JPWO2023053282A1 (es) 2021-09-29 2023-04-06
WO2024022512A1 (en) * 2022-07-29 2024-02-01 Nanjing Legend Biotech Co., Ltd. Claudin-6 binding moieties and uses thereof
WO2024039670A1 (en) * 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP1127119A1 (en) * 1998-11-03 2001-08-29 Adherex Technologies, Inc. Compounds and methods for modulating claudin-mediated functions
EP2264166B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001294198C1 (en) 2000-10-06 2019-04-04 Kyowa Kirin Co., Ltd. Cells producing antibody compositions
WO2002079255A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceuticals Corporation RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII
DE60232265D1 (de) 2001-10-25 2009-06-18 Genentech Inc Glycoprotein-zusammensetzungen
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2379661A1 (en) * 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
EP1571968A4 (en) * 2002-04-16 2007-10-17 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US20060062727A1 (en) * 2002-07-09 2006-03-23 Philips Heidi S Compositions and methods for the diagnosis and treatment of tumor
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
JP2007020155A (ja) 2005-06-08 2007-01-25 Canon Inc 画像処理装置、画像処理方法、プログラム、及び記憶媒体
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP5060068B2 (ja) 2006-06-23 2012-10-31 一般財団法人ファインセラミックスセンター 固体酸化物形燃料電池及びその製造方法

Also Published As

Publication number Publication date
EP2241578A4 (en) 2012-09-12
EP4282428A2 (en) 2023-11-29
EP3064512A3 (en) 2016-10-19
JP5848863B2 (ja) 2016-01-27
EP3064512B1 (en) 2023-08-30
SG187457A1 (en) 2013-02-28
EP3064512A2 (en) 2016-09-07
CN101918450A (zh) 2010-12-15
BRPI0907237A2 (pt) 2015-07-14
JPWO2009087978A1 (ja) 2011-05-26
RU2010133547A (ru) 2012-02-20
WO2009087978A1 (ja) 2009-07-16
AU2009203464A1 (en) 2009-07-16
US9274119B2 (en) 2016-03-01
EP2241578A1 (en) 2010-10-20
CA2711557A1 (en) 2009-07-16
US20110059469A1 (en) 2011-03-10
KR20100116179A (ko) 2010-10-29
EP2241578B1 (en) 2016-04-20
EP4282428A3 (en) 2024-03-20
EP3064512C0 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
MX2010007500A (es) Anticuerpo anti-cldn6.
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
BRPI0607203A2 (pt) anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
MX337600B (es) Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
NZ712693A (en) Compositions and methods for immunotherapy
WO2007126805A8 (en) Cancer immunotherapy compositions and methods of use
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
MXPA06002890A (es) Anticuerpo antiglipicano 3.
MX2011012136A (es) Anticuerpo anti-axl.
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011041613A3 (en) Combination immunotherapy for the treatment of cancer
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012099973A3 (en) Compositions and methods for treating cancer
WO2009078981A3 (en) Ppar-delta ligands and methods of their use
WO2010141738A3 (en) Compositions and method for inhibiting tumor growth
PL1896507T3 (pl) Przeciwciała monoklonalne anty-CD71 i ich zastosowanie do leczenia złośliwych komórek nowotworowych
WO2011057099A3 (en) Treating basal-like genotype cancers
WO2010132389A3 (en) Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
WO2009063970A1 (ja) 抗gpr49抗体を用いる癌の診断および治療
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2009030884A3 (en) Mannosylated butyrophilin tumour markers
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors

Legal Events

Date Code Title Description
FG Grant or registration